Ulinastatin

Ulinastatin, or urinary trypsin inhibitor (UTI) is a glycoprotein that acts as a trypsin inhibitor. It can be derived from urine or synthetically produced. It can be effective in treatment of acute pancreatitis, chronic pancreatitis, toxic shock, Stevens–Johnson syndrome, burns, sepsis, and toxic epidermal necrolysis (TEN).

The drug is used in Japan, where its brand name is Miraclid, as well as in South Korea, China, and India. In India, where it is approved to treat severe sepsis and acute pancreatitis, it is marketed by Bharat Serums and Vaccines Ltd. under the brand name U-Tryp. It is also known by the names Bikunin and Urinastatin.

Effectiveness

Studies in Japan have documented a reduction in the incidence of ERCP-induced pancreatitis with the use of ulinastatin. In one study, the incidence of hyperenzymemia and pancreatitis was significantly lower in the ulinastatin group than in the placebo group.^[1] In another study, ulinastatin reduced serum, drain amylase, and the incidence of postoperative pancreatitis following pancreaticoduodenectomy.^[2]

A study conducted in India found that mortality from all causes over 22 days in subjects with severe pancreatitis was lower among those receiving ulinastatin than those receiving placebo (2.8% versus 18.8%; p=0.048), resulting in a 16% absolute reduction in the risk of death and a relative reduction of 85%. The results indicated that in this population, one life would be saved for every 6.25 subjects treated with ulinastatin. New organ dysfunction was seen in 12 subjects with severe pancreatitis on ulinastatin and 29 on placebo (p=0.0026).^[3]

Mechanism of action

Ulinastatin is an acid-resistant protease inhibitor found in human urine and released from the high-molecular-weight precursor I alpha T1. It inactivates many serine proteases, including trypsin, chymotrypsin, kallikrein, plasmin, granulocyte elastase, cathepsin, thrombin, and factors IXa, Xa, XIa, and XlIa. However, although ulinastatin is a protease inhibitor, its activity toward various proteases is relatively weak.

Ulinastatin protein has been found in the brain, liver, kidney, gastrointestinal tract, cartilage, plasma, ovarian follicular fluid, amniotic fluid, and urine. Its mRNA has been detected only in the liver, kidney, heart, lungs, and pancreas. The presence of ulinastatin in certain tissues appears to be due to diffusional uptake and retention through cell surfaces. Ulinastatin also potentiates local anti-proteolytic activity on the extracellular matrix (ECM) during tissue remodeling, possibly through noncovalent binding to TSG-6.

Its secretion is upregulated by pro-inflammatory cytokines, including IL-6, IL-1beta, and TNF-alpha. These cytokines also enhance the synthesis of intracellular I alpha T1 proteins and IL-1beta upregulated ulinastatin. Ulinastatin is implicated in downregulating or suppressing the production of proMMP-1 and proMMP, prostaglandin H2 synthase-2, urokinase, CXC chemokine, pro-inflammatory cytokines, inducible nitric oxide synthase, tissue factor, P-selectin, intercellular adhesion molecule-1, phosphorylation of the extracellular signal-regulated protein kinases, and NF-kappaB activation.

Ulinastatin also suppresses neutrophil accumulation and activity. The genes and proteins regulated by ulinastatin are implicated in the inflammatory process. Therefore, ulinastatin is not just a protease inhibitor, but can also prevent inflammation and cytokine-dependent signaling pathways. In preclinical and clinical studies, ulinastatin protected against acute lung injury, graft ischemia/reperfusion injury, renal failure after cardiopulmonary bypass, severe burn injury, septic shock, preterm birth, tumor invasion, and metastasis. Its anti-metastatic properties may come from the inhibition of cell-bound plasmin activity. Ulinastatin also prevents tumor progression, partially by inhibiting cathepsin B activity. In particular, ulinastatin is thought to inhibit CD44 dimerization and suppress the MAP kinase signaling cascade, thus preventing ECM degradation, tumor cell invasion, and angiogenesis.

Altogether, ulinastatin plays an important role not only in the protection of organ injury during severe inflammation, but also in the inhibition of tumor invasion and metastasis.^[4]

Dosage and administration

Patients are typically given one or two 100,000 I.U. vials of ulinastatin (reconstituted in 100 ml of dextrose 5% or 100 ml of 0.9% normal saline) by intravenous infusion over the course of one hour, one to three times per day for three to five days. The dosage may be adjusted according to patients' age and the severity of symptoms.^[5]

References

1. ↑ Sujino T, Komatsu Y, Isayama H, Hirano K, Sasahira N, Yamamoto N, Toda N, et al. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: A randomized, controlled trial. Clin Gastroenterol Hepatol2005;3:376.
2. ↑ Uemura K, Murakami Y, Hayashidani Y, Sudo T, Hashimoto Y, Ohge H, Sueda T. Randomized clinical trial to assess the efficacy of ulinastatin for postoperative pancreatitis following pancreaticoduodenectomy. J Surg Oncol2008;98:309-13.
3. ↑ Journal of the association of physicians of India •August 2013 •VOL. 61 :15-18
4. ↑ Inflamm. Res. (2010) 59:679–687 DOI 10.1007/s00011-010-0205-5, J.Clin.Biochem. Nut., 43,139-142, November 2008
5. ↑ https://www.google.co.in/?gws_rd=cr&ei=otZDUomXFYLrrQeE2IGIDg#q=ulinastatin+prescribing+information